Characterization of bone only metastasis patients with respect to tumor subtypes.,npj Breast Cancer

当前位置： X-MOL 学术 › npj Breast Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Characterization of bone only metastasis patients with respect to tumor subtypes.
npj Breast Cancer ( IF 6.5 ) Pub Date : 2018-01-25 , DOI: 10.1038/s41523-018-0054-x
Amanda Parkes ₁ , Katherine Clifton ₁ , Aydah Al-Awadhi ₁ , Oluchi Oke ₁ , Carla L Warneke ₂ , Jennifer K Litton ₃ , Gabriel N Hortobagyi ₃

Affiliation

Metastatic breast cancer (MBC) patients with bone only metastasis (BOM) are a unique population with limited characterization. We identified patients followed at MD Anderson Cancer Center from 01/01/1997 to 12/31/2015 for at least 6 months with a BOM diagnosis as first site of metastasis. Tumor subtype (TS) was assessed by initial breast biopsy immunohistochemistry using hormonal receptor (HR) and HER2 status, with four subtypes identified: HR+/HER2-, HR+/HER2+, HR-/HER2-, HR-/HER2+. HR+ was defined as estrogen receptor or progesterone receptor ≥1%. We identified 1445 patients with BOM, 1048 with TS data available. Among these patients, the majority were HR+/HER2- (78%). Median time from breast cancer diagnosis to first bone metastasis was 2.3 years (95% CI 2.1, 2.5) and varied significantly by TS, with longer time to distant disease in HR+/HER2- patients relative to all other TS (p < .0001). Median overall survival (OS) from breast cancer diagnosis was 8.7 years (95% CI 8.0, 9.7) and varied significantly by TS with poorer OS for HR-/HER2- and HR-/HER2+ patients relative to HR+/HER2- TS (p < .0001). The 442 patients with de novo BOM disease, defined as bone metastasis diagnosis within 4 months of breast cancer diagnosis, had significantly shorter OS (p < .0001). Overall, several higher risk BOM subsets were identified in this analysis, most notably HR-/HER2+ and HR-/HER2- TS and de novo BOM patients.

中文翻译：

关于肿瘤亚型的仅骨转移患者的特征。

具有仅骨转移（BOM）的转移性乳腺癌（MBC）患者是特征有限的独特人群。我们从1997年1月1日至2015年12月31日在MD安德森癌症中心对患者进行了至少6个月的BOM确诊，并将其作为转移的首要部位。通过使用荷尔蒙受体（HR）和HER2状态的初始乳房活检免疫组织化学评估了肿瘤亚型（TS），已鉴定出四种亚型：HR + / HER2-，HR + / HER2 +，HR- / HER2-，HR- / HER2 +。HR +被定义为雌激素受体或孕激素受体≥1％。我们确定了1445例BOM患者，1048例具有TS数据的患者。在这些患者中，大多数为HR + / HER2-（78％）。从乳腺癌诊断到首次骨转移的中位时间为2.3年（95％CI 2.1、2.5），并且因TS而有显着差异，相对于所有其他TS，HR + / HER2-患者的远处疾病发病时间更长（p <.0001）。乳腺癌诊断的中位总体生存期（OS）为8.7年（95％CI 8.0，9.7），并且由于TS而显着变化，相对于HR + / HER2- TS，HR- / HER2-和HR- / HER2 +患者的OS较差（p <.0001）。定义为乳腺癌诊断后4个月内的骨转移诊断的442例从头BOM病患者的OS显着缩短（p <.0001）。总体而言，在此分析中确定了几个较高风险的BOM子集，最著名的是HR- / HER2 +和HR- / HER2-TS以及从头BOM病人。7），相对于HR + / HER2-TS，HR- / HER2-和HR- / HER2 +患者的OS较差，且TS差异显着（p <.0001）。定义为乳腺癌诊断后4个月内的骨转移诊断的442例从头BOM病患者的OS显着缩短（p <.0001）。总体而言，在此分析中确定了几个较高风险的BOM子集，最著名的是HR- / HER2 +和HR- / HER2-TS以及从头开始使用BOM的患者。7），相对于HR + / HER2-TS，HR- / HER2-和HR- / HER2 +患者的OS较差，且TS差异显着（p <.0001）。定义为乳腺癌诊断后4个月内的骨转移诊断的442例从头BOM病患者的OS显着缩短（p <.0001）。总体而言，在此分析中确定了几个较高风险的BOM子集，最著名的是HR- / HER2 +和HR- / HER2-TS以及从头开始使用BOM的患者。

更新日期：2019-01-26

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文